Clinical Trials
37 trialsSAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
Shenzhen Salubris Pharmaceuticals Co., Ltd.
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
MK-7962-012
Merck Sharp & Dohme LLC
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Celgene
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Merck Sharp & Dohme LLC
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Kyntra Bio
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
Hoffmann-La Roche
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Tarix Pharmaceuticals
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Hoffmann-La Roche
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer
TME Pharma AG
Darbepoetin Alfa With or Without Intravenous (IV) Iron
Amgen
Darbepoetin Alfa and Anemia of Cancer
Amgen
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
Amgen
Chemotherapy Related Anemia
Amgen
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
Amgen
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
Amgen
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
Affymax
A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
Kyowa Kirin Co., Ltd.
Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
Centocor, Inc.
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
Amgen
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
Amgen
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
Amgen
Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy
Amgen
Treatment for Patients Suffering From Anemia Due to Chemotherapy
Amgen
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
Amgen